HC Wainwright Forecasts Strong Price Appreciation for Eton Pharmaceuticals (NASDAQ:ETON) Stock

Posted by Brian Himes on Nov 8th, 2026

Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) had its price target raised by HC Wainwright from $70.00 to $80.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright‘s target price would suggest a potential upside of 41.69% from the company’s previous close.

Other analysts also recently issued research reports about the company. B. Riley Financial reiterated a “buy” rating and set a $70.00 price target (up from $40.00) on shares of Eton Pharmaceuticals in a research report on Friday, August 14th. Weiss Ratings raised Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Tuesday, September 22nd. Craig Hallum restated a “buy” rating and issued a $78.00 price objective on shares of Eton Pharmaceuticals in a research report on Thursday, October 15th. Zacks Research raised shares of Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 12th. Finally, Canaccord Genuity Group raised their target price on shares of Eton Pharmaceuticals from $60.00 to $68.00 and gave the company a “buy” rating in a research note on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $77.00.

Read Our Latest Stock Analysis on ETON

Eton Pharmaceuticals Price Performance

NASDAQ:ETON opened at $56.46 on Friday. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of 37.39 and a beta of 0.89. Eton Pharmaceuticals has a 52-week low of $14.27 and a 52-week high of $66.37. The stock has a fifty day moving average of $54.80 and a 200 day moving average of $36.46. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.30 and a current ratio of 1.52.

Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.19. The business had revenue of $57.93 million for the quarter, compared to analyst estimates of $41.98 million. Eton Pharmaceuticals had a return on equity of 144.74% and a net margin of 35.35%. On average, research analysts expect that Eton Pharmaceuticals will post 1.13 EPS for the current fiscal year.

Insider Buying and Selling at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, insider David Krempa sold 25,000 shares of the firm’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $65.07, for a total transaction of $1,626,750.00. Following the sale, the insider owned 37,025 shares in the company, valued at $2,409,216.75. This trade represents a 40.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Paul V. Maier sold 50,000 shares of the firm’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $59.07, for a total value of $2,953,500.00. Following the sale, the director owned 59,745 shares in the company, valued at $3,529,137.15. The trade was a 45.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 79,166 shares of company stock valued at $4,809,672 over the last quarter. 16.49% of the stock is owned by company insiders.

Hedge Funds Weigh In On Eton Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Hilton Head Capital Partners LLC purchased a new position in shares of Eton Pharmaceuticals during the 3rd quarter valued at about $26,000. Sterling Capital Management LLC lifted its position in Eton Pharmaceuticals by 845.7% in the 3rd quarter. Sterling Capital Management LLC now owns 889 shares of the company’s stock worth $46,000 after buying an additional 795 shares during the last quarter. Toth Financial Advisory Corp bought a new stake in Eton Pharmaceuticals in the 2nd quarter worth approximately $43,000. USA Financial Formulas purchased a new stake in Eton Pharmaceuticals in the third quarter worth approximately $62,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Eton Pharmaceuticals in the third quarter worth approximately $75,000. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

Eton Pharmaceuticals News Roundup

Here are the key news stories impacting Eton Pharmaceuticals this week:

Positive Sentiment: Q3 product sales reached a record $57.9 million, up 158% year over year. Eton reported diluted GAAP EPS of $1.06 and non-GAAP EPS of $0.50, and said it exceeded a $200 million annualized revenue run rate five quarters ahead of schedule. Eton Q3 results
Positive Sentiment: Management raised its 2026 revenue outlook to more than $175 million, from more than $145 million, and lifted its adjusted EBITDA margin outlook to above 40%, from above 35%. The stronger forecast reinforces expectations for continued growth and improving profitability. Eton earnings and guidance
Positive Sentiment: Canaccord Genuity and HC Wainwright both raised their price targets to $80 and maintained Buy ratings, signaling confidence in Eton’s prospects. Canaccord Genuity rating HC Wainwright rating
Neutral Sentiment: Eton announced preliminary results from an ET-700 pilot study assessing copper absorption inhibition and gastrointestinal tolerability. The brief report does not provide enough detail to judge the findings’ significance for the pipeline. ET-700 pilot study update

About Eton Pharmaceuticals

(Get Free Report)

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton’s commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.